The neuropathic pain market has traditionally been a poorly defined area, with widely varying drug classes prescribed. With many drugs now in clinical trials for key neuropathic pain sub-types, pharma companies with powerful marketing arms are expected to bring attention to this potentially lucrative market and its considerable unmet needs.
Scope
Overview of patient potential, segmentation by indication and unmet needs in neuropathic pain across the seven major markets
Detailed pipeline analysis for key products in each indication, plus drug sales forecasts to 2014 and clinical trial information
Commercial and clinical attractiveness of late Phase compounds likely to be launched in a neuropathic pain indication
Investigation of the key neuropathic pain subtypes: post-herpetic neuralgia, diabetic neuropathic pain and HIV associated neuropathic pain
Report Highlights Gabapentin remains the gold standard treatment to beat in the 5 EU and US neuropathic pain markets, which are estimated at a combined total of $2,543m in 2005, reaching $4,118m in 2007. However, Japan offers a significantly different market, based on NSAIDs and nerve blockers, and would be a good opportunity for new treatments in neuropathic pain.
The mode of drug delivery has important implications on the ease of drug administration and patient compliance, a key issue in a market where the gold standard has a dosing profile of up to four tablets per day. 20% of the products launched in the forecast are reformulations, with more due to emerge through early Phase trials.
Pfizer's GABA modulator franchise appears safe, and half the brand value of Lyrica (pregabalin) is estimated to be for neuropathic pain. Only Lilly's new antidepressant, Cymbalta (duloxetine) is forecast to compete, but cheaper generic gabapentin offers significant competition to all novel products launching at a premium brand price.
Reasons to Purchase
Understand key market drivers and predict the future performance of key compounds
Quantify the future size and scope of market and potential for novel molecular-targeted treatments in neuropathic pain
Benchmark pipeline agents against currently marketed products and market needs
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
